Cargando…
P111: COVID-19 IN PATIENTS WITH THALASSEMIA AND SICKLE CELL DISEASE: A SINGLE CENTER EXPERIENCE
Autores principales: | Dimopoulou, M, Komninaka, V, Flevari, P, Bartzi, V, Repa, K, Voskaridou, E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811849/ http://dx.doi.org/10.1097/01.HS9.0000821536.28990.38 |
Ejemplares similares
-
5613475 ADVERSE REACTIONS TO RBC TRANSFUSION: A SINGLE THALASSEMIA AND SICKLE CELL DISEASE DEPARTMENT’S EXPERIENCE
por: Xydaki, A.X., et al.
Publicado: (2023) -
P116: THE IMPACT OF COVID19 PANDEMIC ON SICKLE CELL MANAGEMENT: EXPERIENCE OF A SINGLE PEDIATRIC CENTER
por: Maria Vousvouki, M, et al.
Publicado: (2022) -
P134: THE AREAL PROJECT: A VIRTUAL REALITY APPLICATION TO SUPPORT THE THERAPEUTIC EXPERIENCE AND THERAPY EDUCATION OF ADULT PATIENTS WITH THALASSEMIA AND SICKLE CELL DISEASE
por: Megale, V, et al.
Publicado: (2022) -
5610178 SURVIVAL AND COMPLICATIONS IN PATIENTS WITH HEMOGLOBINOPATHIES: THE EXPERIENCE OF A SINGLE DEPARTMENT OF THALASSEMIA AND SICKLE DISEASE
por: Xydaki, X.A., et al.
Publicado: (2023) -
P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG?
por: F., GALACTÉROS, et al.
Publicado: (2022)